Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2018

View Archived Issues

Crinetics Pharmaceuticals awarded NIDDK grants

iTeos Therapeutics completes series B financing to support immuno-oncology programs

Biocad initiates phase I study of BCD-132 in patients with multiple sclerosis

First-in-human data presented for oncolytic virus Celyvir in solid tumors

Lilly's acquisition of ARMO BioSciences complete

Phase I results available for CUDC-907 in pediatric solid tumors

ARQ-531 demonstrates preliminary signs of antitumor activity in B-cell malignancies

AZD-9567 shows better therapeutic ratio than prednisolone in vivo and in clinical setting

FDA awards orphan drug designation to PCS-499 for necrobiosis lipoidica

Ohara Pharmaceutical obtains certain rights to compound from PRISM Pharma

City of Hope studies memory-enriched T cells in recurrent or refractory glioma

IMpower133 study of Tecentriq in extensive stage SCLC meets coprimary endpoints

Erytech refocuses development efforts with eryaspase

YH-25448 demonstrates promising antitumor activity in patients with EGFR T790M-positive NSCLC

Prefusion F protein respiratory syncytial virus vaccine DS-Cav1 safe in first-in-human study

FDA clears IND for pivotal trial of INP-104 for acute treatment of migraine

J-TEC signs license agreement for low-cost manufacturing technology of CAR-T cells

Cellenkos and University of Texas enter neuroinflammation research collaboration

DSMB of Aladote phase Ib/IIa study to treat paracetamol poisoning finds no safety concerns

Merrimack discontinues development of MM-141 for pancreatic cancer following CARRIE results

CellCentric initiates first-in-man study of CCS-1477 for late-stage prostate cancer

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...